Beijing Beilu Pharmaceutical Co Ltd. Stock Analysis 300016.SZ

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of contrast agents, and central nervous system and hypoglycemic drugs. The company is headquartered in Beijing, Beijing and currently employs 1,188 full-time employees. The company went IPO on 2009-10-30. The chemical drug business mainly focuses on the research, development, production and sales of contrast agents, hypoglycemic drugs and other products. The traditional Chinese medicine segment mainly focuses on the production and sales of central nervous system, heat-clearing and detoxifying, and tonic products. The firm's main products include gadopentetate dimeglumine injection, iohexol injection, repaglinide tablets, iohexol active pharmaceutical ingredient, Jiuwei Zhenxin Granules, Jinlianhua Granules, Qingwei Huanglian Pills and others. The firm mainly operates its businesses in the domestic and overseas markets.